A Phase 3 interventional study of PF-08653944 and Placebo in Obesity, Overweight and/or Obesity and Overweight, sponsored by Pfizer. Active, not recruiting at 180 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing berobenatide in Obesity — 11 open to participants now, 15 under way, 12 of them phase 3. berobenatide · Obesity.
Among the 21 studies testing berobenatide in Obesity, this one is the 2nd largest by enrollment, is one of 15 that started in 2026, is one of 12 in phase 3, reaches primary completion later than 4 of the 14 other live ones, and was the 7th registered.
11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.
Browse Obesity studies →11 of the 21 studies testing berobenatide in Obesity are open now, in 12 countries. Recruiting first, the newest first:
Pfizer · Sites in China
Ages 18+
Pfizer · Sites in United States
Ages 18+
Pfizer · Sites in United States, Canada
Ages 18+
Pfizer · Sites in United States
Ages 18+ · Healthy volunteers
Pfizer · Sites in Japan
Ages 18+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 5 · Phase 3 12
First in 2024; this study’s year is marked. 15 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,078 is above the median of 67 across 9,016 interventional studies indexed under Obesity.
Median enrollment 258 across the 21 interventional studies. Of the 6 that completed or were terminated, 1 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 21 have an industry lead sponsor. The 2 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
64 studies in Obesity by Pfizer: 13 open now, 19 under way, 12 of them phase 3. Of 43 finished, 11 (26%) have results posted.
Among the 64 studies in Obesity by Pfizer, this one is the 4th largest by enrollment of the 62 interventional ones that give a count, is one of 19 that started in 2026, is one of 16 in phase 3, reaches primary completion later than 7 of the 18 other live ones, and was the 46th registered.
Pfizer’s Obesity studies by the year they started, since 2004.
5 of the studies testing berobenatide in Obesity that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07311850Phase 3PfizerEfficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity | 2027-09-21 |
| NCT07400653Phase 3PfizerA Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D) | 2027-10-12 |
| NCT07508241PfizerA Study to Learn About the Effect of Study Medicine Called PF-08653944 on How Quickly the Stomach Empties Its Content in Healthy Adults With Overweight or Obesity | 2027-01-27 |
| NCT07845513PfizerA Study to Learn About the Study Medicine Called PF-08653944 in Otherwise Healthy Chinese Adults With Overweight or Obesity | 2027-02-21 |
| NCT07876531PfizerA Study to Learn How Different Forms of the Study Medicine Called Berobenatide is Taken up Into the Blood in Adults With Overweight or Obesity | 2027-04-06 |
Add all 5 to your calendar (.ics) → With an account.
Among the 21 studies testing berobenatide in Obesity, from their registry updates:
Among Pfizer’s 64 in Obesity:
This tab as a report to print or save as PDF → With an account.
The purpose of this clinical study is to learn about the safety and effects of the study medicine to help adults with obesity or overweight and type 2 diabetes lose weight. Being overweight or obese means carrying too much body weight. Type 2 diabetes is a condition where there is too much sugar in the blood.
The study medicine is given by a shot under the skin in the belly area. The participants will be trained to do this at home once every week.
About 660 out of 1000 adults will also receive the study medicine and about 330 out of 1000 adults will receive placebo. A placebo does not have any medicine in it but looks just like the medicine being studied. The investigators will compare the experiences of people receiving the study medicine to those of the people who do not. This will help us assess if the study medicine is safe and effective.
People will take part in this study for about 21 months. During this time, they will have about 14 study visits at the site and 5 over the phone.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Have value between ≥6.5% (48 mmol/mol) and ≤10.0% (86.0 mmol/mol) at Screening with stable therapy for at least 90 days prior to Screening/Visit 1. T2DM may be treated with:
--Diet and exercise alone or in combination with: Any oral antidiabetic therapy per local labeling EXCEPT DPP-4 inhibitors. Participant may NOT be on GLP-1 agonists or insulin
Participants must be motivated and willing to:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive matching placebo by Subcutaneous Injection.
Other: Placebo
Participants will receive PF-08653944 by Subcutaneous Injection.
Drug: PF-08653944
Participants will receive PF-08653944 by Subcutaneous Injection.
Drug: PF-08653944
Participants will receive PF-08653944 by Subcutaneous Injection.
Drug: PF-08653944
By Subcutaneous Injection
Also known as: MET097
By Subcutaneous Injection
Percent Change from baseline in body weight
Time frame: Baseline, Week 64
Change from baseline in body weight
Time frame: Baseline, Week 64 and 84
Change in HbA1c (%) from baseline
Time frame: Baseline, Week 64 and 84
Percentage of Participants achieving ≥5% of body weight reduction from baseline
Time frame: Baseline, Week 64 and 84
Percentage of Participants achieving ≥10% of body weight reduction from baseline
Time frame: Baseline, Week 64 and 84
Percentage of Participants achieving ≥15% of body weight reduction from baseline
Time frame: Baseline, Week 64 and 84
Percentage of Participants achieving ≥20% of body weight reduction from baseline
Time frame: Baseline, Week 64 and 84
Change from baseline in Fasting triglycerides
Time frame: Baseline, Week 64 and 84
Change from baseline in Non-high-density lipoprotein cholesterol (non-HDL-C)
Time frame: Baseline, Week 64 and 84
Change from baseline in Systolic Blood Pressure (SBP)
Time frame: Baseline, Week 64 and 84
Change from baseline in Short Form 36 health survey (SF-36) physical function domain score
Time frame: Baseline, Week 64 and 84
Percent change from baseline in body weight
Time frame: Baseline, Week 84
Change from baseline in waist circumference
Time frame: Baseline, Week 64 and 84
Percentage of Participants Achieving HbA1c <7%
Time frame: Week 64 and Week 84
Percentage of Participants Achieving HbA1c ≤6.5%
Time frame: Week 64 and Week 84
Percentage of Participants Achieving HbA1c <5.7%
Time frame: Week 64 and Week 84
Change from Baseline in Fasting Glucose
Time frame: Baseline, Week 64 and 84
Change from Baseline in Fasting insulin
Time frame: Baseline, Week 64 and 84
Change from baseline in Total Cholesterol
Time frame: Baseline, Week 64 and 84
Change from baseline in Low-density lipoprotein cholesterol
Time frame: Baseline, Week 64 and 84
Change from baseline in Very low-density lipoprotein cholesterol
Time frame: Baseline, Week 64 and 84
Change from baseline in High-density lipoprotein cholesterol
Time frame: Baseline, Week 64 and 84
Change from Baseline in Diastolic Blood Pressure (DBP)
Time frame: Baseline, Week 64 and 84
Percent change from baseline in high-sensitivity C-reactive protein
Time frame: Baseline, Week 64 and 84
Change from Baseline in EuroQoL 5-Dimension 5-Level (EQ5D-5L)
Time frame: Baseline, Week 64 and 84
Change from Baseline in Control of Eating Questionnaire (CoEQ)
Time frame: Baseline, Week 64 and 84
Change from Baseline in Food Noise Questionnaire (FNQ)
Time frame: Baseline, Week 64 and 84
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
Time frame: Week 84
Number of Participants with Serious adverse events (SAEs)
Time frame: Week 84
Number of Participants with Adverse Events of Clinical Interest (AECIs)
Time frame: Week 84
Number of Participants With Clinical Laboratory Abnormalities
Time frame: Week 84
Number of participants with anti-drug antibodies (ADAs)
Time frame: Week 84
Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) of PF-08653944
Time frame: Week 84
Showing the first 100 of 180 sites across 11 countries. Choose a country and city above to see the rest.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Started Feb 2026 (actual). Primary completion is estimated for Oct 2027, 19 months after the start.
Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's planned 19 months is close to that.
Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Berobenatide